@article {Hurford2020.11.04.20226316, author = {Amy Hurford and James Watmough}, title = {Don{\textquoteright}t wait, re-escalate: delayed action results in longer duration of COVID-19 restrictions}, elocation-id = {2020.11.04.20226316}, year = {2020}, doi = {10.1101/2020.11.04.20226316}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Non-pharmaceutical public health interventions have significant economic and social costs, and minimizing their duration is paramont. Assuming that interventions are sufficient to reduce infection prevalence, we use a simple linear SIR model with case importation to determine the relationship between the timing of restrictions, duration of measures necessary to return the incidence to a set point, and the final size of the outbreak. The predictions of our linear SIR model agree well with COVID- 19 data from Atlantic Canada, and are consistent with the predictions of more complex deterministic COVID-19 models. We conclude that earlier re-escalation of restrictions results in shorter disruptions, smaller outbreaks, and consequently, lower economic and social costs. Our key message is succinctly summarized as {\textquoteleft}don{\textquoteright}t wait, re-escalate{\textquoteright} since delaying re-escalation of restrictions results in not only in more infections, but also longer periods of restrictions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAH and JW are funded by each by NSERC Discovery Grants and the AARMS Centre for Disease Modelling.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NoneAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code are available at the link provided. https://github.com/ahurford/reescalation-chapter}, URL = {https://www.medrxiv.org/content/early/2020/11/06/2020.11.04.20226316.1}, eprint = {https://www.medrxiv.org/content/early/2020/11/06/2020.11.04.20226316.1.full.pdf}, journal = {medRxiv} }